CMC Pharmaceuticals Formulary Advisory Board

CMC Pharmaceuticals, a supplier of medicinal product development services to the pharmaceutical industries and biotechnology industries, formed an advisory board. The leadership group will advise CMC Pharma on continuous growth with a focus on cutting edge science, business strategy, marketing and risk reduction. Members have decades of experience in government, commercial, and academic research and development with demonstrated success, including several biotech start-ups.

Board members include Drs. John Patton, Mark Prausnitz, W. Mark Saltzman, Arthur Tipton, and Larry Zeitlin. The CMC Pharma team, led by owner and co-founder Dr. Mike Radomsky, assists customers in their pharmaceutical product development efforts, from early formulation and analytical methods to commercial-stage support.

“The CMC Pharma team has decades of experience in technical drug development, rapid response times and the current ability to start new projects,” said Dr. Radomsky. “Forming an advisory board allows us to network and strategize with academics and industry leaders, navigating new avenues of expansion while continuing to use our strengths to our advantage.”

Dr. Art Tipton, President, is an independent consultant who helps companies develop the next generation of drug administration some products. He was part of three successful drug delivery companies, including the founder and CEO of Brookwood Pharmaceuticals, now part of Evonik. He holds 43 US patents and is an elected member of the National Academy of Inventors, the College of Fellows of the American Institute of Medical and Biological Engineering, the Controlled Release Society, and the National Academy of Engineers.

Dr. John Patton spent the first 16 years of his career in academia as a lipid biochemist and marine biologist. He then left for lead Genentech’s drug delivery team in 1985. Since then, he has gained extensive experience in drug delivery startups in the biotech industry, where he co-founded Inhale/Nektar Therapeutics, Dance BioPharm, InCarda and iPharma Limited. He is now CEO of Tesio Pharmaceuticals and founding investor of Halozyme. Dr. Patton is a member of the Controlled Release Society.

Dr. Mark Prausnitz is Full Professor and J. Erskine Love, Jr. Chair in Chemical and Biomolecular Engineering at the Georgia Institute of Technology. He holds a BS from Stanford University and a Ph.D. from MIT, both in chemical engineering. He has published over 300 journal articles and co-founded seven start-up companies, including Micron Biomedical and Clearside Biomedical.

Dr. W. Mark Saltzman is an engineer and educator who has authored three textbooks and served as a faculty member at Johns Hopkins University, Cornell University, and Yale University. He is the founding chair of Yale’s Department of Biomedical Engineering and principal of Jonathan Edwards College at Yale. He has been recognized for his excellence in research and teaching and has received numerous awards and has been elected a Fellow of the American Institute for Medical and Biological Engineering, Biomedical Engineering Society, etc.

Dr. Larry Zeitlin received his Ph.D. in Reproductive Biology from Johns Hopkins University and was a Research Scientist at ReProtect and Principal Investigator at Epicyte Pharmaceuticals. He co-founded Mapp Biopharmaceutical and ZabBio, and is chairman of both companies. His career has focused on the development of monoclonals antibody based on fatty acids to address unmet public health needs for infectious diseases.


Comments are closed.